滋阴润燥丸对干燥综合征模型小鼠颌下腺炎症及功能作用研究

doi:10.12092/j.issn.1009-2501.2026.02.007

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (2): 196-203.doi: 10.12092/j.issn.1009-2501.2026.02.007

滋阴润燥丸对干燥综合征模型小鼠颌下腺炎症及功能作用研究

漆文霞¹(), 王钢¹, 闫彦峰²^,*(), 田杰祥¹, 刘海龙¹, 魏勇¹^,³, 王嘉³

1. 甘肃中医药大学附属医院，兰州 730020，甘肃
2. 甘肃中医药大学第四附属医院，兰州 730060，甘肃
3. 甘肃中医药大学，兰州 730000，甘肃

收稿日期:2024-09-25 修回日期:2024-12-27 出版日期:2026-02-26 发布日期:2026-03-17
通讯作者: 闫彦峰 E-mail:2716633581@qq.com;847044189@qq.com
作者简介:漆文霞，女，在读博士，从事中西医结合防治风湿病研究。E-mail：2716633581@qq.com
基金资助:
国家自然科学基金项目（81860858）；国家自然科学基金项目（81960832）；甘肃省科技厅自然科学基金项目（22JR11RA131，24JRRA1038）；中国中医药管理局建设项目-中医循证能力建设项目（2101704）；甘肃省名中医传承工作室建设项目（2100601）；甘肃省卫生健康行业科研项目（GSWSHY-8-2024）；甘肃省中医药管理局高水平重点课题（CZKZ-2025-37）；甘肃省科技与自然科学基金（24JRRA1038）；甘肃省卫生健康行业项目优秀青年人才项目（GSWSQN-2024-08）

Study on the effect of ZiYin RunZao (ZYRZ) pill on the inflammation and function of submandibular gland in mice with Sjögren's syndrome

Wenxia QI¹(), Gang WANG¹, Yanfeng YAN²^,*(), Jiexiang TIAN¹, Hailong LIU¹, Yong WEI¹^,³, Jia WANG³

1. Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Lanzhou 730020, Gansu, China
2. The Fourth Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Lanzhou 730060, Gansu, China
3. Gansu University of Traditional Chinese medicine, Lanzhou 730000, Gansu, China

Received:2024-09-25 Revised:2024-12-27 Online:2026-02-26 Published:2026-03-17
Contact: Yanfeng YAN E-mail:2716633581@qq.com;847044189@qq.com

摘要/Abstract

摘要：

目的: 探讨滋阴润燥丸对干燥综合征模型小鼠颌下腺炎症及功能的作用。方法: 将40只8周龄NOD/Ltj小鼠随机分为5组：模型组、西药组及滋阴润燥丸高中低剂量组，每组8只。另ICR小鼠8只为空白组。适应性喂养1周后开始干预。高、中、低剂量组分别予以1.78、0.89、0.45 mg/kg的滋阴润燥丸灌胃，西药组予以60 mg/kg羟氯喹灌胃，空白组及模型组均给予等量无菌蒸馏水灌胃，每日1次，连续8周。期间第0、2、4、6、8周监测小鼠饮水量。干预结束后，取小鼠颌下腺和血清。HE染色法观察颌下腺组织病理情况；ELISA法检测血清中炎性细胞因子IFN-γ、IL-10、TNF-α的水平。RT-qPCR法检测小鼠颌下腺组织中AQP5、M3R mRNA表达水平；Western blot法检测小鼠颌下腺组织中AQP5、M3R的蛋白表达；免疫组化法检测颌下腺组织中AQP5蛋白表达水平。结果: 与正常组比较，模型组小鼠饮水量明显增加（P<0.05），小鼠血清中IFN-γ、TNF-α表达显著升高（P<0.05），IL-10表达显著降低（P<0.05）；AQP5、M3R mRNA、蛋白表达显著降低（P<0.05）；与模型组相比，西药组、滋阴润燥丸高中剂量组小鼠饮水量明显减少（P<0.05），血清中IFN-γ、TNF-α表达显著降低（P<0.05），IL-10表达显著升高（P<0.05），AQP5、M3R mRNA、蛋白表达显著升高（P<0.05）。结论: 滋阴润燥丸能够降低干燥综合征模型小鼠颌下腺炎症反应，改善颌下腺分泌功能。

关键词: 滋阴润燥丸, 干燥综合征, 颌下腺, 炎症, 分泌功能

Abstract:

AIM: To investigate the effect of ZiYin RunZao (ZYRZ) pill on the inflammation and function of submandibular gland in mice modeled with Sj?gren's syndrome. METHODS: Forty 8-week-old NOD/Ltj mice were randomly divided into five groups: model group, western medicine group, and the high, middle and low dosage groups of ZYRZ, with eight mice in each group. Another 8 ICR mice were blank group. The intervention was started after 1 week of acclimatization feeding. In the high, medium and low dose groups, 1.78, 0.89 and 0.45 mg/kg of ZYRZ pills were administered by gavage, respectively; in the western medicine group, 60 mg/kg of hydroxychloroquine was administered; and in the blank group and the model group, equal amounts of sterile distilled water were administered by gavage once a day for eight consecutive weeks. The body weight and water intake of the mice were monitored at weeks 0, 2, 4, 6 and 8. At the end of the intervention, mice submandibular gland and serum were taken, and the histopathology of submandibular gland was observed by HE staining; the levels of inflammatory cytokines IFN-γ, IL-10, and TNF-α were detected in serum by ELISA; the levels of AQP5 and M3R mRNA were detected in submandibular gland by RT-qPCR; the levels of AQP5 and M3R mRNA in submandibular gland were detected in submandibular gland by Western blot; and the levels of AQP5 and M3R mRNA in submandibular gland were detected in submandibular gland by RT-qPCR. AQP5, M3R protein expression; immunohistochemistry to detect the level of AQP5 protein expression in the submandibular gland tissue of mice. RESULTS: Compared with the normal group, mice in the model group showed no significant changes in body weight, significantly increased water intake (P<0.05), significantly higher expression of IFN-γ and TNF-α in serum of mice (P<0.05), and significantly lower expression of IL-10 (P<0.05); significantly lower expression of mRNA and protein of AQP5 and M3R (P<0.05); compared with the model group, the western blot and the ZYRZ Pill in high school and the western blot were detected in the submaxillary gland tissues of mice; immunohistochemical method was used to detect the expression level of AQP5 in the submaxillary gland tissues. Compared with the model group, mice in the western medicine group and the high school dose group of ZYRZ consumed significantly less water (P<0.05), the expression of IFN-γ and TNF-α in serum was significantly reduced (P<0.05), the expression of IL-10 was significantly elevated (P<0.05), and the expression of AQP5, M3R mRNA, and protein was significantly elevated (P<0.05). CONCLUSION: ZYRZ pill can reduce the inflammatory reaction of submandibular gland in mice with Sj?gren's syndrome model and improve the secretion function of submandibular gland.

Key words: ZiYin RunZao pill, Sjgren's syndrome, submaxillary gland, inflammation, secretory function

中图分类号:

漆文霞, 王钢, 闫彦峰, 田杰祥, 刘海龙, 魏勇, 王嘉. 滋阴润燥丸对干燥综合征模型小鼠颌下腺炎症及功能作用研究[J]. 中国临床药理学与治疗学, 2026, 31(2): 196-203.

Wenxia QI, Gang WANG, Yanfeng YAN, Jiexiang TIAN, Hailong LIU, Yong WEI, Jia WANG. Study on the effect of ZiYin RunZao (ZYRZ) pill on the inflammation and function of submandibular gland in mice with Sjögren's syndrome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 196-203.

图/表 8

表 1

Table 1 qPCR primers

Gene	Primer type	Primer sequence
AQP5	Forward	CATGAACCCAGCCCGATCTT
AQP5	Reverse	CTCAGCGAGGAGGGGAAAAG
M3R	Forward	ACGAACAACAAAACGAGCCG
M3R	Reverse	AGATGACCGTTTCGTGCCTT

表 2

Table 2 Comparison of water intake among different groups of mice ($ \overline{x} $±s, n=8)

Group	Dose (g/kg)	Daily water intake (g)
Group	Dose (g/kg)	0 week	2 weeks	4 weeks	6 weeks	8 weeks
Normal	-	3.82±0.08	3.98±0.11	4.16±0.09	4.27±0.12	4.44±0.07
Model	-	4.11±0.08^b	4.65±0.20^b	5.18±0.15^b	5.41±0.34^b	6.20±0.18^b
Hydroxychloroquinb sulfatb	60 mg/kg	4.25±0.09^b	4.60±0.13^b	4.77±0.15^be	4.75±0.15^be	4.69±0.13^be
Ziyinrunzao pill low	0.45	4.20±0.11^b	4.50±0.11^b	4.81±0.09^be	4.86±0.13^be	4.97±0.28^be
Ziyinrunzao pill medium	0.89	4.28±0.09^b	4.43±0.09^b	4.70±0.24^be	4.68±0.19^be	4.64±0.17^be
Ziyinrunzao pill high	1.78	4.26±0.09^b	4.50±0.15^b	4.77±0.08^be	4.73±0.07^be	4.68±0.07^be

图 1

Fig.1 Pathological changes of SMG in different groups of mice (HE staining, 200x) NC: Normal group; MC: Model group; HCQ: Hydroxychloroquinb sulfatb group; ZL: Ziyinrunzao pill low group; ZM: Ziyinrunzao pill medium group; ZH: Ziyinrunzao pill high group.

表 3

Table 3 Comparison of IFN-γ, IL-10, and TNF-α levels in serum of different groups of mice ($ \overline{x} $±s, n=8)

Group	Dose (g/kg)	IFN-γ (ng/L)	IL-10 (pg/mL)	TNF-α (ng/L)
Normal	-	169.75±26.52	326.27±31.78	175.01±20.04
Model	-	365.43±34.30^b	205.98±30.51^b	381.01±37.32^b
Hydroxychloroquinb sulfatb	60 mg/kg	289.5±24.32^be	243.43±36.44^be	287.68±29.90^be
Ziyinrunzao pill low	0.45	293.83±32.59^be	235.09±26.00^be	298.74±27.61^be
Ziyinrunzao pill medium	0.89	260.80±35.17^be	285.39±45.16^be	281.61±18.16^be
Ziyinrunzao pill high	1.78	217.92±20.53^be	297.84±26.99^be	249.25±27.98^be

表 4

Table 4 Comparison of AQP5 and M3R mRNA in SMG tissues of different groups of mice ($ \overline{x} $±s, n=8)

Group	Dose (g/kg)	AQP5	M3R
Normal	-	1.31±0.09	1.54±0.11
Model	-	0.62±0.06^b	0.54±0.07^b
Hydroxychloroquinb sulfatb	60 mg/kg	0.89±0.02^be	1.00±0.11^be
Ziyinrunzao pill low	0.45	1.02±0.04^be	0.73±0.09^be
Ziyinrunzao pill medium	0.89	0.91±0.06^be	1.08±0.04^be
Ziyinrunzao pill high	1.78	0.95±0.03^be	1.18±0.06^be

图 2

Fig.2 Comparison of AQP5 and M3R mRNA in SMG tissues of different groups of mice ($ \overline{x} $±s, n=8) NC: Normal group; MC: Model group; HCQ: Hydroxychloroquinb sulfatb group; ZL: Ziyinrunzao pill low group; ZM: Ziyinrunzao pill medium group; ZH: Ziyinrunzao pill high group. bP<0.05, compared with normal group; eP<0.05, compared with model group.

图 3

Fig.3 Comparison of AQP5 and M3R protein levels in SMG tissues of different groups of mice ($ \overline{x} $±s, n=8) NC: Normal group; MC: Model group; HCQ: Hydroxychloroquinb sulfatb group; ZL: Ziyinrunzao pill low group; ZM: Ziyinrunzao pill medium group; ZH: Ziyinrunzao pill high group. bP<0.05, compared with normal group; eP<0.05, compared with model group.

图 4

Fig.4 Comparison of AQP5 protein levels in SMG tissues of different groups of mice (IHC, $ \overline{x} $±s, n=8) NC: Normal group; MC: Model group; HCQ: Hydroxychloroquinb sulfatb group; ZL: Ziyinrunzao pill low group; ZM: Ziyinrunzao pill medium group; ZH: Ziyinrunzao pill high group. bP<0.05, compared with normal group; eP<0.05, compared with model group.

参考文献 30

1	Lal S. Primary Sjögren's syndrome[J]. N Engl J Med, 2018, 379 (1): 96- 97. doi: 10.1056/NEJMc1804598
2	Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis[J]. Ann Rheum Dis, 2015, 74 (11): 1983- 1989. doi: 10.1136/annrheumdis-2014-205375
3	Zhang Q, Lv X, Wang Y, et al. Expression of CFTR, a hallmark gene of ionocytes, is downregulated in salivary glands of Sjögren's syndrome patients[J]. Arthritis Res Ther, 2022, 24 (1): 263. doi: 10.1186/s13075-022-02959-8
4	Bjordal O, Norheim KB, Rødahl E, et al. Primary Sjögren's syndrome and the eye[J]. Surv Ophthalmol, 2020, 65 (2): 119- 132. doi: 10.1016/j.survophthal.2019.10.004
5	Horeth E, Oyelakin A, Song EC, et al. Transcriptomic and single-cell analysis reveals regulatory networks and cellular heterogeneity in mouse primary Sjögren's syndrome salivary glands[J]. Front Immunol, 2021, 12, 729040. doi: 10.3389/fimmu.2021.729040
6	Kroese FGM, Haacke EA, Bombardieri M. The role of salivary gland histopathology in primary Sjögren's syndrome: promises and pitfalls[J]. Clin Exp Rheumatol, 2018, 112 (3): 222- 233.
7	Jonckheere S, Adams J, de Groote D, et al. Epithelial-mesenchymal transition (EMT) as a therapeutic target[J]. Cells Tissues Organs, 2021, 5, 1- 26. doi: 10.3389/978-2-83251-634-8
8	邹芳霞, 王钢, 漆文霞. 基于“肺与大肠相表里”理论探讨滋阴润燥丸治疗原发性SS[J]. 中医药临床杂志, 2022, 34 (2): 211- 214.
9	Roszkowska AM, Rauz S, Szczepańska A, et al. Ophthalmologic manifestations of primary Sjögren's syndrome[J]. Genes (Basel), 2021, 12 (4): 542.
10	Singh N, Cohen PL. The T cell in sjogren's syndrome: Force majeure, not spectateur[J]. Autoimmun, 2012, 39 (3): 229- 233. doi: 10.1016/j.jaut.2012.05.019
11	Zhao H, Li Q, Ye M, et al. Tear luminex analysis in dry eye patients[J]. Med Sci Monit, 2018, 24, 7595- 7602. doi: 10.12659/msm.912010
12	Chen X, Aqrawi LA, Utheim TP, et al. Elevated cytokine levelsin tears and saliva of patients with primary Sjögren's syndrome correlate with clinical ocular and oral manifestations[J]. Sci Rep, 2019, 9, 7319. doi: 10.1038/s41598-019-43714-5
13	Yin H, Vosters JL, Roescher N, et al. Location of immunization and interferon-gamma are central to induction of salivary gland dysfunction in Ro60 peptide immunized model of Sjogren's syndrome[J]. PLoS One, 2011, 6, e18003. doi: 10.1371/journal.pone.0018003
14	Torres-Aguilar H, Sosa-Luis SA, Aguilar-Ruiz SR. Infections as triggers of flares in systemic autoimmune diseases: Novel innate immunity mechanisms[J]. Curr Opin Rheumatol, 2019, 31, 525- 531. doi: 10.1097/BOR.0000000000000630
15	Yoshimura S, Nakamura H, Horai Y, et al. Abnormal distribution of AQP5in labial salivary glands is associated with poor saliva secretion in patients with Sjögren's syndrome including neuromyelitis optica complicated patients[J]. Mod Rheumatol, 2016, 26, 384- 390. doi: 10.3109/14397595.2015.1083146
16	Caraba A, Iurciuc S, Nicolin M, et al. Endothelial dysfunction in primary Sjögren's syndrome: correlation with serum biomarkers of disease activity[J]. Int J Mol Sci, 2023, 24 (18): 13918. doi: 10.3390/ijms241813918
17	Abe S, Tsuboi H, Kudo H, et al. M3 muscarinic acetylcholine receptor-reactive Th17 cells in primary Sjögren's syndrome[J]. JCI Insight, 2020, 5 (15): e135982.
18	Steinfeld S, Cogan E, King LS, et al. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren syndrome patients[J]. Lab Invest, 2001, 81 (2): 143- 148. doi: 10.1038/labinvest.3780221
19	Ishibashi K, Kondo S, Hara S, et al. The evolutionary aspects of aquaporin family[J]. Am J Physiol Regul Integr Comp Physiol, 2011, 69 (3): R566- R576. doi: 10.1007/978-94-024-1057-0_2
20	Tzartos JS, Stergiou C, Daoussis D, et al. Antibodies to aquaporins are frequentin patients with primary Sjögren's syndrome[J]. Rheumatology (Oxford), 2017, 56 (12): 2114- 2122. doi: 10.1093/rheumatology/kex328
21	Konttinen YT, Tensing EK, Laine M, et al. Abnormal distribution of aquaporin-5 in salivary glands in the NOD mouse model for Sjögrens syndrome[J]. J Rheumatol, 2005, 32 (6): 1071- 1075.
22	李晓宇, 韩星海. SS与水通道蛋白-5[J]. 中华风湿病学杂志, 2017, 11 (6): 378- 380.
23	阮光峰. 水通道蛋白5在SS发病机制中的作用研究进展[J]. 同济大学学报: 医学版, 2016, 37 (2): 113- 117.
24	Lee SM, Lee SW, Kang M, et al. FoxO1 as a regulator of aquaporin 5 expression in the salivary gland[J]. Dent Res, 2021, 100 (11): 1281- 1288. doi: 10.1177/00220345211003490
25	Alam J, Koh JH, Kwok SK, et al. Functional epitopes for anti-aquaporin 5 antibodies in Sjögren syndrome[J]. J Rheumatol, 2017, 44 (9): 1317- 1325. doi: 10.1177/0022034517717965
26	Shaalan A, Carpenter G, Proctor G. Epithelial disruptions, but not immune cell invasion, induced secretory dysfunction following innate immune activation in a novel model of acute salivary gland injury[J]. Oral Pathol Med, 2018, 47 (2): 211- 219. doi: 10.1111/jop.12663
27	Nguyen CQ, Peck AB. The interferon-signature of Sjögren's syndrome: How unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases[J]. Front Immunol, 2013, 4, 142. doi: 10.3389/fimmu.2013.00142
28	Mona M, Mondello S, Hyon JY, et al. Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary Sjögren's syndrome[J]. Clin Exp Rheumatol, 2021, 39 (4): 795- 803. doi: 10.55563/clinexprheumatol/gy6udz
29	Choi SS, Jang E, Jang K, et al. Autoantibody-mediated dysfunction of salivaryglands leads to xerostomia in SKG mice[J]. Immune Network, 2019, 19 (6): e44. doi: 10.4110/in.2019.19.e44
30	秦源, 林崇泽, 孙晗, 等. 滋阴润燥丸对SS颌下腺细胞AQP5及M3R表达的影响[J]. 中国中医急症, 2017, 26 (1): 5- 8.

[1]	虞旭友, 张启祥, 刘嘉莉, 王广基, 周芳. 间充质干细胞衍生细胞外囊泡用于炎症性肠病的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(2): 247-256.
[2]	沈小平, 吴东, 于丽丽, 吴斌. 糖酵解-乳酸化修饰在哮喘中的潜在作用与治疗展望[J]. 中国临床药理学与治疗学, 2026, 31(1): 96-106.
[3]	文一如, 杨金拉姆, 美嘎, 李娜, 录亚鹏, 张琰, 刘婕婷. 巨噬细胞极化与肠道菌群及其代谢产物在器官损伤中相关研究进展[J]. 中国临床药理学与治疗学, 2026, 31(1): 125-132.
[4]	靳丽丽, 郄涛, 李立琴. 司美格鲁肽通过调控AMPK/mTOR/ULK1通路介导的自噬减轻缺氧/复氧AC16人心肌细胞炎症损伤[J]. 中国临床药理学与治疗学, 2025, 30(8): 1058-1066.
[5]	王倩, 梁昌昌, 沈士朋, 刘茂东, 白璐. IL-33/ST2信号通路在肾脏疾病中作用机制的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(8): 1122-1126.
[6]	黄运超, 王益琼, 张婷, 张鋆, 李兰, 张玲. 西红花酸通过抗炎促血管新生改善糖尿病下肢缺血作用研究[J]. 中国临床药理学与治疗学, 2025, 30(7): 899-906.
[7]	苏红, 程骞, 王雅轩, 戴重阳, 赵富邦, 蒲小燕. 高海拔低氧暴露后中性粒细胞胞外诱捕网释放与高原肺水肿相关微循环障碍的动态变化研究[J]. 中国临床药理学与治疗学, 2025, 30(6): 732-740.
[8]	高子恬, 陈彧, 贺海东, 唐余燕. 短链脂肪酸调控NLRP3炎症小体通路在慢性肾脏病中的作用及中药干预的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(6): 812-819.
[9]	许婷婷, 汪万杰, 鲍静, 夏瑞祥. NLRC4介导的炎症小体通路与多发性骨髓瘤的关系及治疗前景[J]. 中国临床药理学与治疗学, 2025, 30(4): 501-508.
[10]	崔涵雨, 胡长平. 巨噬细胞极化与心血管疾病研究进展[J]. 中国临床药理学与治疗学, 2025, 30(4): 548-555.
[11]	李晓楠, 李阳, 许张茜, 康淑珍, 孔丽, 张志平. 靶向递送策略在炎症性肺部疾病中的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(3): 313-324.
[12]	刘静, 侯凯, 张丽. 紫铆因改善非酒精性脂肪性肝炎及作用机制研究[J]. 中国临床药理学与治疗学, 2025, 30(3): 355-365.
[13]	张国华, 汪湛东, 漆文霞, 张琪琪, 田杰祥, 张延英, 郭超, 汪永锋. B淋巴细胞在原发性干燥综合征发病机制中的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(12): 1722-1728.
[14]	田杰祥, 漆文霞, 王钢, 闫彦峰, 汪湛东, 魏勇, 刘海龙, 张媛媛. 唾液腺上皮细胞在干燥综合征中的病理作用研究进展[J]. 中国临床药理学与治疗学, 2025, 30(11): 1550-1558.
[15]	董家珊, 陈嘉睿, 曾大勇, 刘亦伟, 许建文, 林荣芳. 炎症性肠病患者GST基因多态性与硫唑嘌呤活性代谢物6-TGN浓度水平相关性研究[J]. 中国临床药理学与治疗学, 2025, 30(10): 1383-1390.

滋阴润燥丸对干燥综合征模型小鼠颌下腺炎症及功能作用研究

Study on the effect of ZiYin RunZao (ZYRZ) pill on the inflammation and function of submandibular gland in mice with Sjögren's syndrome

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 8

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价